News Sanofi

Stocks

SAN

FR0000120578

Pharmaceuticals

Market Closed - Euronext Paris Other stock markets 19:55:00 09/06/2026 +04			5-day change	1st Jan Change
77.04 ^EUR	+0.48%		+4.93%	-6.87%

06-09	Kymera Therapeutics Unlocks $20 Million Milestone After Dosing First Participant in KT-485 Phase 1 Trial	MT
06-09	SANOFI : Deutsche Bank remains its Buy rating	ZD

All News

Mentions Relevance

06-09	SANOFI : Deutsche Bank remains its Buy rating	ZD
06-08	Sanofi Receives European Commission Approval For Sarclisa Subcutaneous As First Anticancer Treatment Administered Via On-Body Injector	CI
06-08	Sanofi's Subcutaneous Sarclisa Approved in EU Across Multiple Myeloma Indications	MT
06-08	Sanofi Wins EU Approval for Subcutaneous Sarclisa in Multiple Myeloma	MT
06-08	Brussels greenlights subcutaneous administration for Sanofi's Sarclisa
06-08	Sanofi’s Sarclisa subcutaneous approved in the EU as the first anticancer treatment administered via an on-body injector	GL
06-05	Owkin And Sanofi Enter Multi-Year Collaboration To Co-Develop Next-Generation Biopharma Agents Backed By Five-Year License For K Pro	CI
06-04	Sanofi federates the healthcare ecosystem to accelerate the diagnosis of rare diseases in France, Biogen joins accelRare	AQ
06-04	Sanofi among top performers as Jefferies reiterates Buy rating
06-04	Sanofi to launch global employee share ownership plan
06-04	Sanofi launches 2026 global employee stock purchase plan	GL
06-04	SANOFI : Gets a Buy rating from Jefferies	ZD
06-02	UPC Turns Three: Statistics, Milestones, And Trends	AQ
05-29	Sanofi's Immune Thrombocytopenia Therapy Secures Regulatory Approval in UK	MT
05-29	UK's MHRA approves rilzabrutinib to treat adults with immune thrombocytopenia	RE
05-29	Sanofi's venglustat granted priority review by the FDA for treatment of GD3 (May 28)	RE
05-29	Sanofi's venglustat accepted for priority review in the US to treat type 3 Gaucher disease	AQ
05-28	US FDA advisers vote in favor of recommending COVID vaccines target XFG variant	RE
05-28	Sanofi says manufacturing XFG protein Nuvaxovid vaccine as its single global COVID-19 product for the 2026-27 season: briefing docs	RE
05-28	SANOFI : Deutsche Bank maintains a Buy rating	ZD
05-28	Sanofi Granted FDA Priority Review for Potential Treatment of Rare Gaucher Disease	MT
05-28	The US Food and Drug Administration Accepts Sanofi?s venglustat for priority review in the US to treat type 3 Gaucher disease	CI
05-28	Sanofi granted Priority Review for Gaucher disease treatment
05-28	Sanofi's Type 3 Gaucher Treatment Secures US FDA Priority Review Status	MT
05-28	Sanofi's venglustat granted priority review by the FDA for treatment of MG3	RE